Heavy metal legend diagnosed with lymphoma
According to information released by a publicist of the band Black Sabbath, guitarist Tommy Iommi has been diagnosed with lymphoma.
The only hint of the gravity of the disease was that it had been found in the early stages. The band, which has been recording the first new album from the original foursome in over three decades in Los Angeles, said they will move operations from LA to England to make things easier on Iommi as he begins unidentified treatment.
Last year, Iommi published his autobiography, "“Iron Man: My Journey Through Heaven and Hell with Black Sabbath." The band had originally scheduled the launch of their world tour to begin in Moscow in late May, but with the diagnosis it is possible that this will be delayed.
The band has asked fans to send "positive vibes" to the legendary guitarist as he considers his treatment options.
Source: New York Daily News
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
